Al Sandrock

Al Sandrock is the current Director at Verge Genomics. Prior to this, Al was an Outsourcing Associate/Scientific Researcher at Genentech from April 2014 to October 2019 where they managed all aspects of outsourcing activities and operations including budgeting, quotation, negotiation, PO generation, shipping logistics, and payment. Al also liaised between CROs and internal scientists, updating departmental SOPs in order to streamline and improve current practices. Furthermore, Al collaborated with cross-functional teams to achieve business, operations, and quality objectives.

Before Genentech, Al worked as a Research Associate at Hoffmann-La Roche from August 2010 to October 2012. During this time, Al worked on four different series compounds for the ERa program with the aim to identify a contingency back up with equivalent or better potency than GDC-0927 and improve PK properties. Additionally, Al synthesized a novel series of drug-like compounds with four chiral centers via 10-step synthesis for PIM project.

Al Sandrock earned their BS in Pharmaceutical Chemistry from China Pharmaceutical University. Al then went on to earn their MS in Medicinal Chemistry from Shanghai Institute of Pharmaceutical Industry.